FOXP3 and neoplasm: Countering the HATs, the HDACs deacetylate FOXP3, which reduces Treg development and immunosuppressive function, and also provides a therapeutic target for enhancing immunosuppressive (and potentially anti-tumor) activity in patients [79-81].